Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|April 20, 2022

Takeda’s TAKHZYRO Prefilled Syringe Now Available for Patients with Hereditary Angioedema

Takeda’s TAKHZYRO prefilled syringe is now available for patients with hereditary angioedema aged 12 years and older in the United States.

Takeda announced on April 18, 2022 that its treatment TAKHZYRO (lanadelumab-flyo) injection single-dose prefilled syringe is now available in the United States to prevent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.

HAE is a rare genetic disease that causes recurrent attacks of swelling in various parts of the body, which can be burdensome, debilitating, and potentially life-threatening. The treatment is ready-to-use and is easier to administer as it requires fewer preparation steps than a single-dose vial. FDA approved the treatment on Feb. 8, 2022.

“HAE attacks are unpredictable, debilitating, and in some cases life-threatening, adding uncertainty and complexity to the daily lives of those living with this disease and their families,” said Dr. William Lumry, allergy immunology specialist, clinical professor of internal medicine, University of Texas Southwestern Medical School, in a press release. “After many years in practice witnessing the ups and downs of this disease, I welcome any opportunity to simplify the process of administering an effective prevention therapy for people living with HAE."

“By introducing TAKHZYRO prefilled syringe to the HAE community, our aim is to continue to enhance the patient experience. With this advancement, those taking TAKHZYRO can now live their life with a ready-to-use option that requires fewer steps and less waste than when using the single-dose vial to receive their injection,” said Cheryl Schwartz, senior vice president, Rare Disease Business Unit at Takeda Pharmaceutical Company Limited, in the release. “Over the coming months, we will be working with patients and their specialty pharmacies as they are ready to make the transition.”

Source: Takeda

Related to this article

View more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more